Navigation Links
Discovery Labs Reports First Quarter 2012 Financial Results
Date:5/3/2012

d Drug Administration (FDA); (ii) non-cash items related to depreciation and stock-based compensation of $0.7 million and $0.5 million for 2012 and 2011, respectively; and (iii) in the first quarter of 2011, grant revenue of $0.4 million related to funds received and expended under a Fast Track Small Business Innovation Research Grant (SBIR) from the National Institutes of Health to support the development of aerosolized KL4 surfactant for respiratory distress syndrome.  Excluding these one-time, non-recurring items and non-cash items related to depreciation and stock-based compensation, the operating loss was $5.4 million and $5.9 million for 2012 and 2011, respectively.

Operating cash outflows for the first quarter of 2012 were $5.7 million and net cash inflows for the first quarter, after taking into consideration financing activities, were $44.6 million. 

As of March 31, 2012, the Company had cash and cash equivalents of $54.8 million.  During the first quarter of 2012, the Company raised $50.3 million consisting of (i) $42.1 million in net proceeds from a March 2012 public offering of 16.1 million shares of common stock at a price of $2.80 per share;  (ii) $6.7 million in proceeds from the exercise of warrants to purchase 2.3 million shares of common stock; and, (iii) $1.5 million net proceeds from the an offering of 350,374 shares of common stock that was concluded in March 2012 under its "at-the-market" (ATM) Program.

The Company had 43.4 million and 24.6 million shares of common stock outstanding as of March 31, 2012 and December 31, 2011, respectively.

Additionally, the Company currently has: (i) outstanding warrants to purchase 2.8 million shares of common stock at an exercise price of $2.94 that expire on May 22, 2012, which if exercised by the holders could result in up to an additional $8.1 million in proceeds; (ii) its ATM Program, which may allow the Company, at its discretion, to
'/>"/>

SOURCE Discovery Laboratories, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Genomic Health and OncoMed Announce Strategic Alliance for Biomarker Research and Discovery Using Next Generation Sequencing
2. AnaptysBio Announces Antibody Discovery Partnership With Gilead Sciences
3. UWM discovery advances graphene-based electronics
4. Mars, Incorporated Answers Question: How Does Feeding People and Pets Nurture Science and Discovery? At TEDMED 2012
5. AlphaBio Centrix, LLC Announces a New Discovery for Programming Energetic Patches
6. Discovery in Nature elucidates immune cells in skin and supports novel vaccine approach
7. Thomson Reuters Cortellis Drives Drug Discovery and Development With Powerful New Web Services
8. Discovery opens door to low-cost negative refraction, new products and industries
9. AnaptysBio Announces New Strategic Antibody Discovery
10. Thomson Reuters Research Forecasts the Onset of the Targeted Drug Discovery Era
11. Discovery of a dark state could mean a brighter future for solar energy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... , May 21, 2015  The EveryLife ... Hatch (R-UT) and Amy Klobuchar ... Now Accelerating Cures & Treatments, or OPEN ACT. ... disease patient advocacy organizations, this bipartisan legislation promises ... affordable medicines to rare disease patients by incentivizing ...
(Date:5/21/2015)... 2015 As part of its philanthropic ... Sun Health Foundation funded a $3.25 million project to ... with the most up-to-date features and technology. , The ... pharmacy's 45 staff members will begin moving from the ... the coming days. , The current pharmacy has ...
(Date:5/20/2015)... Calif. , May 20, 2015 ... today presented preliminary data demonstrating the ability of ... pulmonary fibrosis (IPF) from other interstitial lung diseases ... suggest the classifier,s potential to help thousands of ... resolve ambiguity in IPF diagnosis – a frequent ...
(Date:5/20/2015)... 2015 The global genotyping market is ... the forecast period of 2015 to 2020 to reach ... in drug discovery and development process and to provide ... addition to this,heavy investments by key manufacturers to offer ... propelling market growth. Browse 113 market data tables & ...
Breaking Biology Technology:Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2Sun Health Foundation Provides $3.25M to Expand, Relocate Banner Del E. Webb Medical Center Pharmacy 2Sun Health Foundation Provides $3.25M to Expand, Relocate Banner Del E. Webb Medical Center Pharmacy 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 2Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 4Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 5Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 2Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 3Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 4Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 5
... chemists have developed a new model to predict the ... finding could help inform the design of tailored nano-structures, ... fields, including the remote sensing of atmospheric pollutants and ... nano-particles play a key role in atmospheric processes as ...
... Biotechnology, Inc. (OTC: CSBR) ("Champions") announced today the ... Inc. in which Champions will conduct low passage ... an inhibitor of mutant B-Raf, and CEP-37440, a ... determine the activity or response in potential clinical ...
... Health Diagnostic Laboratory, Inc. (HDL, Inc.) and BG Medicine, Inc. ... which HDL, Inc. will offer galectin-3 testing services based on ... Medicine Galectin-3 Test was recently cleared by the FDA as ... heart failure. Elevated galectin-3 levels are associated with an inherently ...
Cached Biology Technology:UBC researchers develop new model to predict the optical properties of nano-structures 2Champions Announces Technology Collaboration Utilizing Champions' Tumorgraft™ Technology Platform for Oncology Drug Development 2Champions Announces Technology Collaboration Utilizing Champions' Tumorgraft™ Technology Platform for Oncology Drug Development 3Health Diagnostic Laboratory, Inc. (HDL, Inc.) Announces Availability of Galectin-3 Testing Service in Partnership With BG Medicine 2Health Diagnostic Laboratory, Inc. (HDL, Inc.) Announces Availability of Galectin-3 Testing Service in Partnership With BG Medicine 3Health Diagnostic Laboratory, Inc. (HDL, Inc.) Announces Availability of Galectin-3 Testing Service in Partnership With BG Medicine 4
(Date:5/19/2015)... , May 19, 2015 ... has announced the addition of the  "Genetic ... offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent ... an in-depth analysis of the current and ... of gene-based tests, their working principles and ...
(Date:5/14/2015)... , May 14, 2015  Verificient Technologies, ... verification and online remote proctoring, announced a ... (SaaS) company and creator of the Canvas ... the two companies will benefit from the ... As a fully integrated multifactor ...
(Date:5/11/2015)... May 11, 2015 Curemark LLC, a privately ... of a new Phase III double blind, randomized, placebo-controlled ... formulation, CM-AT, on all children ages 3-8 with Autism. ... Phase III double blinded clinical trial for CM-AT in ... of the digestive enzyme chymotrypsin. This new trial will ...
Breaking Biology News(10 mins):Global Genetic Testing Market Outlook 2018 2Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2
... a world-leading provider of scientific, technical and medical information products ... by the European Menopause and Andropause Society (EMAS) in journal ... postmenopausal women with summary recommendations. Vitamin D deficiency is ... is classified as a public health issue as it can ...
... billion-dollar-a-year industry in the United States that aims to create ... But a new analysis of restoration projects shows that restored ... "Once you degrade a wetland, it doesn,t recover its normal ... carbon, which both affect natural cycles of water and nutrients, ...
... hydrothermal sea vents go dormant and their blistering warmth turns to ... replaced. A team led by USC microbiologist Katrina Edwards found ... spewed by active hydrothermal vents are supplanted, once the vents go ... that make up the vents themselves. These findings based ...
Cached Biology News:Elsevier's Maturitas publishes position statement on the role of vitamin D in postmenopausal women 2Restored wetlands rarely equal condition of original wetlands 2Restored wetlands rarely equal condition of original wetlands 3Life discovered on dead hydrothermal vents 2
... media are rigid macroporous hydrophilic media. The ... at moderate pressures, while the macroporous beads ... hydrophilic matrix reduces nonspecific binding. Macro-Prep High ... exchanger with very high flow rates and ...
... collection of phage display libraries, human ... and mouse tissues. All cDNA libraries ... size of cDNA inserts has been ... 1000bp by gel electrophoresis of DNA ...
... Corticosterone kit is a competitive enzymeimmunoassay (EIA) ... mouse or rat serum or plasma. Corticosterone ... in rats and mice, and in most ... reptiles. Most mammals produce both corticosterone and ...
Mouse monoclonal [1.F.1] to Yersinia pestis F1 antigen ( Abpromise for all tested applications). Antigen: Purified F1 antigen of Y. pestis vaccine strain EB....
Biology Products: